Welcome to our dedicated page for Immucell SEC filings (Ticker: ICCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles ImmuCell Corporation’s (Nasdaq: ICCC) SEC filings, giving investors structured access to the company’s regulatory disclosures as an animal health business focused on dairy and beef cattle. ImmuCell’s filings include current reports on Form 8-K, annual reports on Form 10-K and quarterly reports on Form 10-Q, along with other exhibits and agreements.
Through these documents, readers can review ImmuCell’s reported product sales for its First Defense® line, commentary on trends in domestic and international sales, and management’s discussion of gross margins, net income or loss, and backlog dynamics. Filings also describe the development status of Re-Tain®, including the New Animal Drug Application process, investigational product use, and the company’s decision to pause further direct investment after receiving an FDA Incomplete Letter related to a contract manufacturer.
ImmuCell’s SEC reports provide detail on financing arrangements, such as loan agreements and lines of credit with Maine Community Bank, refinancing transactions, and related security interests in company assets. They also disclose corporate governance and leadership changes, including CEO succession, board expansion, and executive employment agreements, as well as other material definitive agreements.
On Stock Titan, these filings are updated in near real time as they are posted to the EDGAR system. AI-powered summaries help explain lengthy 10-K and 10-Q reports, highlight key risk factors and business updates, and clarify the implications of Form 8-K events. Users can also quickly identify information about executive and board changes, financing obligations and other material developments affecting ImmuCell’s cattle health-focused operations.
ImmuCell (ICCC) filed a Form 3 reporting initial beneficial ownership for its President and CEO. The filing lists three nonqualified stock options to purchase Common Stock at an exercise price of $5.90 per share, covering 25,327, 25,327, and 25,329 shares. These options become exercisable on 09/16/2026, 09/16/2027, and 09/16/2028, respectively, and each expires on 09/16/2035. The grant was made in connection with an offer letter outlining the terms of his employment and vests in three increments as shown.
ImmuCell Corporation announced governance changes tied to its CEO transition. Effective November 1, 2025, Olivier te Boekhorst became President and CEO, while Michael F. Brigham stepped down from his roles as President, CEO, Secretary, and Treasurer to serve as Special Advisor to the CEO. On October 29, 2025, the Board expanded from seven to nine directors and elected Mr. te Boekhorst and CFO Timothy C. Fiori as directors. Mr. Fiori was also elected Secretary and Treasurer. Neither executive was appointed to any Board committees.
ImmuCell Corporation filed a current report to let investors know it has released preliminary, unaudited product sales figures for the quarter ended September 30, 2025. The company communicated these early sales results through a press release dated October 7, 2025, which is included as Exhibit 99.1 to the report. The exhibit is designated as “furnished” rather than “filed,” meaning it is provided for information purposes under securities rules without being incorporated into other filings unless specifically referenced.
ImmuCell Corporation appointed Olivier te Boekhorst as President and CEO effective November 1, 2025. He joins from Archimed and previously held senior roles at IDEXX Laboratories and Boston Consulting Group. His compensation package includes a $450,000 base salary, up to $400,000 annual cash bonus tied to financial improvement targets, a $100,000 one-time signing bonus (repayable in certain circumstances), and initial equity awards: a nonqualified option for 76,673 shares at $5.90 and a second grant of up to 85,000 shares (accounting value $250,000). Equity awards vest over three years and accelerate on a Change in Control. The Board will expand and elect him as a director. The existing CEO will transition to Special Advisor during a handover period.
ImmuCell Corporation entered into an Allonge to and Amendment of its existing line of credit with Maine Community Bank. This agreement extends the Company’s $1 million line of credit through September 11, 2026, allowing continued access to this borrowing capacity.
Borrowings under the line of credit will bear interest at a variable rate equal to the National Prime Rate per annum. The extension represents an ongoing banking relationship rather than a new borrowing and is documented as a material definitive agreement and direct financial obligation.
ImmuCell Corporation entered into a Loan Agreement and Promissory Note with Maine Community Bank for total loan proceeds of $2,327,119 at a fixed interest rate of 6.5% per annum. The proceeds were used to pay off an existing Maine Community Bank loan with an outstanding balance of $1,525,852 bearing interest at 7% and a Finance Authority of Maine loan with an outstanding balance of $768,209 bearing interest at 8%, effectively consolidating those obligations into a single loan.
The new loan is secured by a security interest in substantially all of the Company’s assets, and the lender may accelerate repayment if the Company fails to make timely payments or otherwise comply with the loan terms. The Loan Agreement and Promissory Note are filed as Exhibits 10.1 and 10.2, and a related press release is filed as Exhibit 99.1.
ImmuCell Corporation (NASDAQ:ICCC) filed an 8-K announcing the initiation of a CEO succession planning process. The filing discloses that current President and CEO Michael F. Brigham will be part of this transition. The company has begun searching for new leadership, though no specific timeline was provided. This represents a significant corporate governance development for ImmuCell, as leadership transitions can materially impact company strategy and operations.